News
Second, we built a culture that values impact over broad activity. As AI increasingly handles routine tasks that once ...
9h
TipRanks on MSNRegeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis TreatmentRegeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...
Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...
21d
Zacks Investment Research on MSNSanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...
Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a third program and agreeing to sponsor a trial of its partner’s lead candidate.
Sanofi wins ‘Top GCC of 2025’ and ‘GCC Country Leader of the Year’ at Zyoin Group workplace summit and awards 2025: Our Bureau, Bengaluru Monday, July 14, 2025, 15:30 Hrs ...
14d
GlobalData on MSNSanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDPIn Japan alone, around 4,000 individuals have a CIDP diagnosis. Sanofi neurology development global head Erik Wallstroem stated: “The orphan drug designation of riliprubart for ...
Investing.com -- Sanofi (EPA: SASY) (NASDAQ: SNY) has started shipping its flu vaccine portfolio for the 2025-2026 season to health facilities across the United States, the company announced today.
Sanofi has agreed to make strategic investment of up to US$25 million in Adagene. The Company plans to use the proceeds to fund its research and development activities, including clinical development ...
Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...
Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 10 and set a price target of €95.00. The company’s shares closed yesterday at $98.70. Elevat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results